Syndax Pharmaceuticals Inc Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Syndax Pharmaceuticals Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Syndax Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $11.9M, a 43.4% increase year-over-year.
  • Syndax Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $39.1M, a 45.4% increase year-over-year.
  • Syndax Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2023 was $31M, a 93.2% increase from 2022.
  • Syndax Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2022 was $16M, a 20.3% increase from 2021.
  • Syndax Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2021 was $13.3M, a 47% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $31M +$14.9M +93.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $16M +$2.7M +20.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $13.3M +$4.26M +47% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $9.06M +$3.05M +50.8% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $6.01M -$196K -3.16% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $6.2M +$751K +13.8% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-12
2017 $5.45M +$742K +15.8% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-05
2016 $4.71M +$826K +21.3% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-07
2015 $3.88M +$1.63M +72% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 $2.26M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.